Upon opening an R&D center in Mississauga in 2017, Biolab Pharma Canada, headed by Paulo Wickbold Marques, became the first Brazilian pharmaceutical company to establish an affiliate in Canada. In this interview, Paulo describes Biolab's bold leap from Latin America, the strengths of the Canadian pharmaceutical landscape and how the climate and Canadian skillset are helping to turn Biolab into a multinational business.
You have been in Canada for two years now and the R&D center in Mississauga opened in late 2017. What were your first impressions of the Canadian market?
"At Biolab, we searched for a country where innovation is a top priority, and Canada fits this criterion: the country offers the most fertile research landscape, and we are an innovative company that wants to get ahead in R&D."
